# Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

> **NCT00191009** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 124 (—)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** atomoxetine hydrochloride
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00191009
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 124 (—)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191009, "Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00191009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*